Same Indication

Nivolumab vs Warfarin

Nivolumab vs Warfarin: Overview

This comparison examines the pharmacological differences between Nivolumab and Warfarin.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Warfarin: Inhibits vitamin K epoxide reductase complex.

Pharmacokinetics

Half-life: Nivolumab — 27 days; Warfarin — 20-60 hours.

Chemical Properties

Molecular Formula: Warfarin — C19H16O4.

Molecular Weight: Warfarin — 308.3280 g/mol.

Type: Nivolumab — Antibody; Warfarin — Small molecule.